Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Neuroblastoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

X-Rays 7Phantoms, Imaging 7Magnetic Resonance Spectroscopy 7Specimen Handling 6Nuclear Medicine Department, Hospital 5Biopsy 4tazemetostat 3Cyclophosphamide 3ulixertinib 2tipifarnib 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vincristine 2Topotecan 2Methotrexate 2LY3023414 2Etoposide 2Cisplatin 2Carboplatin 2talazoparib 1selinexor 1pembrolizumab 1olaparib 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdoid Tumor × Eflornithine × 90 days × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡